|Day Low/High||160.41 / 161.81|
|52 Wk Low/High||133.65 / 179.92|
Plus, an FDA advisory panel gives a unanimous boost to a Moderna booster shot and Boeing slumps on a negative news report.
As you mark your October calendar for what I shared earlier, also keep your eyes on Oct. 14-15. Those are the days a panel of FDA advisors will meet to discuss whether to recommend booster shots of Covid-19 vaccines from Moderna and Johnson & Johnso...
Let's look at that recent downgrade of 'dull' Morgan Stanley and see why exciting is best left for the stadiums and amusement parks -- and not stocks.
Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.
It was as if markets heard what they wanted to hear, when it was actually much more simple: markets heard exactly what they had anticipated.
How come this decision was so opaque to so many?
It's time to turn to the chart to determine whether the pullback is an opportunity to buy or if it is something more.
I could be wrong, but as far as I can tell, nobody else is telling the story about the sudden movement in these yields.
The fiscal football remains a greater threat this week than anything Fed Chair Jerome Powell says on Zoom this Friday.
Investors come into this week with 'all eyes' on the Kansas City Fed's economic symposium come week's end.
AbbVie has been a Sarge fave for a long time. Sarge has been rewarded for trusting this firm's management when they acquired Allergan as a means toward replacing expected reductions in cash flows moving forward as the firm's patents for winder dru...
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
These guys are aware that the U.S. was energy independent less than a year and a half ago, right?
One thing we know is that the current wave of the pandemic just seems to be getting worse.
Imagine if the SEC did not prohibit underwriters from lending out shares to short-sellers for 30 days after an IPO?
The Delta virus has more power to control both fiscal and monetary policy than does the data or do any of our leaders individually.
Also, there's reason to turn J&J's one shot jab into a two shot vaccine just like the rest.
Break in! sold off just now on this tweet: *FDA EXPECTED TO ANNOUNCE NEW WARNING ON J&J COVID VACCINE: WAPO This should help with the vaccine uptake — zerohedge (@zerohedge) July 12, 2021
And I was right, and the cynics were wrong. Here's why that matters more than ever now.
Here's where traders could probe the long side of JNJ.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
Probably the best news right now is that individual stock picking has improved.
High-quality drugmaker AbbVie has several promising products aside from Humira and the market has priced the stock at a bargain.
Debt-free and poised to gain from its COVID-19 vaccine demand, MRNA could inject some life into your investment plan.
These Dividend Aristocrats have free DRIPs, long histories of raising their dividends, and attractive yields well above the market average.